Literature DB >> 8236775

Development of neutralizing antibody in horses infected with Ehrlichia risticii.

Y Rikihisa1, R Wada, S M Reed, S Yamamoto.   

Abstract

The role of the humoral immune response in ehrlichial infection is unknown. Development of neutralizing antibodies during a course of Ehrlichia risticii infection in a pony was examined in vitro by determining the inhibition of E. risticii infection of P388D1 cells in the presence of the sera. The pony experimentally infected with E. risticii developed significant neutralizing activity in the sera by 15 days postinfection when parasitemia started to decline. Neutralizing activity continued to rise after recovery from the disease up to 34 days postinfection at which time the experiment was terminated. In vitro neutralizing activities in the sera from 3 additional ponies infected with E. risticii were lower at 2 weeks than at 4 weeks postinfection. The sera from vaccinated/challenged ponies had comparable neutralizing activity to those of the recovered ponies at approximately 3 to 4 weeks postchallenge. Equine sera from infected or vaccinated/challenged ponies were also effective in protecting mice from E. risticii infection. These studies demonstrated the significant development of neutralizing activity in the sera of recovered or vaccinated/challenged ponies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8236775     DOI: 10.1016/0378-1135(93)90135-t

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  7 in total

1.  Comparison of PCR and culture to the indirect fluorescent-antibody test for diagnosis of Potomac horse fever.

Authors:  J Mott; Y Rikihisa; Y Zhang; S M Reed; C Y Yu
Journal:  J Clin Microbiol       Date:  1997-09       Impact factor: 5.948

2.  Association of deficiency in antibody response to vaccine and heterogeneity of Ehrlichia risticii strains with Potomac horse fever vaccine failure in horses.

Authors:  S K Dutta; R Vemulapalli; B Biswas
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

3.  Anti-Ehrlichia chaffeensis antibody complexed with E. chaffeensis induces potent proinflammatory cytokine mRNA expression in human monocytes through sustained reduction of IkappaB-alpha and activation of NF-kappaB.

Authors:  E H Lee; Y Rikihisa
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

4.  Analysis of 16S rRNA and 51-kilodalton antigen gene and transmission in mice of Ehrlichia risticii in virgulate trematodes from Elimia livescens snails in Ohio.

Authors:  M Kanter; J Mott; N Ohashi; B Fried; S Reed; Y C Lin; Y Rikihisa
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

5.  Inhibition of binding, entry, or intracellular proliferation of Ehrlichia risticii in P388D1 cells by anti-E. risticii serum, immunoglobulin G, or Fab fragment.

Authors:  J B Messick; Y Rikihisa
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

6.  Pathogenic, immunologic, and molecular differences between two Ehrlichia risticii strains.

Authors:  R Vemulapalli; B Biswas; S K Dutta
Journal:  J Clin Microbiol       Date:  1995-11       Impact factor: 5.948

7.  Antigenic, morphologic, and molecular characterization of new Ehrlichia risticii isolates.

Authors:  W Chaichanasiriwithaya; Y Rikihisa; S Yamamoto; S Reed; T B Crawford; L E Perryman; G H Palmer
Journal:  J Clin Microbiol       Date:  1994-12       Impact factor: 5.948

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.